Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

m early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... , SUNNYVALE, Calif., Oct. 13 Cepheid (Nasdaq: CPHD ... its third quarter ended September 30, 2009, on Wednesday, October ... company will host a management presentation at 2 p.m. Pacific ... To access the live webcast, please visit Cepheid,s website ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today that it ... from the National Institute of Allergy and Infectious Diseases (NIAID) ... from the NIAID is to support a segment of the ... particle-based vaccine. RSV is the most commonly identified cause ...
... CAMBRIDGE, Mass., Oct. 13 Cequent Pharmaceuticals, a pioneer ... treatments to prevent and treat human disease, announced that ... Cequent,s planned launch of its clinical program and highlight ... for 3 p.m. on Tuesday, October 27, 2009, at ...
Cached Biology Technology:Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 3Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27 2
(Date:9/2/2014)... September 2, 2014 Best-selling author Sam Kean stops ... the Megalodon, the 50-foot super shark that, despite what ... extinct. Learn all about it at http://youtu.be/KhFygIoW_MA . ... Tales of Madness, Love and the History of the ... getting the Reactions treatment in a 10-episode video series ...
(Date:9/2/2014)... done in by it. New research at Rockefeller University ... gap in mice with very similar genetic backgrounds ... the development of psychiatric disorders such as anxiety and ... as it goes through its life. And we suspect ... genes, and as a result, affect an animal,s susceptibility ...
(Date:9/1/2014)... the U.S. undergoes a battery of tests designed to ... Thousands of children born in the developing world, however, ... the disease each year. , A.J. Kumar hopes ... those deaths. , A Post-Doctoral Fellow in Chemistry ... Whitesides, the Woodford L. and Ann A. Flowers University ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... school students and teachers sounds like a witches brew for an ... Instead, these are the components that comprise the ... developed by researchers at Washington University in St. Louis and a ... Lars Angenent, Ph.D., assistant professor of ...
... a pair of proteins that work in concert to restart ... dormancy. The Hawley Lab has described the dual ... that awakens the long-dormant egg, allowing for production of a ... Dec. 4, 2007 issue of PLoS Biology. The ...
... may have begun in the protected spaces inside of layers ... new hypothesis. The hypothesis was developed by Helen Hansma, ... and a program director at the National Science Foundation. Hansma ... Dec. 4, at the annual meeting of the American Society ...
Cached Biology News:Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3Stowers Institute's Hawley Lab identifies factors responsible for restart of meiotic cycle 2New hypothesis for origin of life proposed 2
... Blot Processing Standard Tray (3 ... for gel staining and blot processing.Automated ... gels for proteins and nucleic acid ... detection and chromogenic detection.Programmable control of ...
... Dithiothreitol, 1 g. High quality ... sample preparation that give consistent ... cells and tissues.Clean up samples ... volumes. Accurately quantitate protein for ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
Biology Products: